BAX Stock Recent News

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2023 financial results on Thursday, November 2, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c.

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2024. About Baxter Every day, mil.

Although there has been a steady decline in the inflation rate in response to the Fed's aggressive rate hike plan, investors still have concerns about a potential rece

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer is scheduled to present at 8:45 a.m. EST. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 5, 2024. About Baxter Every day, millions of patients and caregive.

Baxter International has seen 7 consecutive years of dividend growth, but has not raised its dividend this year. The company's financials show slow revenue growth and a dramatic drop in earnings. Baxter's stock price has declined significantly over the past five years, making it a less attractive investment option compared to peers.

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Income investors tend to focus on stocks with high dividend yields. This is understandable, as investors such as retirees need current income.